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Abstract 
Filamin-A, also called Actin Binding Protein-280, is not only an essential component of the 
cytoskeleton networks, but also serves as the scaffold in various signaling networks. It has 
been shown that filamin-A facilitates DNA repair and filamin-A proficient cells are more re-
sistant to ionizing radiation, bleomycin, and cisplatin. In this study, we assessed the role of 
filamin-A in modulating cancer cell sensitivity to Topo II poisons, including etoposide and 
doxorubicin. Intriguingly, we found that cells with filamin-A expression are more sensitive to 
Topo II poisons than those with defective filamin-A, and filamin-A proficient xenograft mel-
anomas have better response to etoposide treatment than the filamin-A deficient tumors. 
This is associated with more potent induction of DNA double strand breaks (DSBs) by Topo 
II poisons in filamin-A proficient cells than the deficient cells. Although the expression of 
filamin-A enables cells a slightly stronger capability to repair DSB, the net outcome is that 
filamin-A proficient cells bear more DSBs due to the significantly enhanced DSB induction by 
Topo II poisons in these cells. We further found that filamin-A proficient cells have increased 
drug influx and decreased drug efflux, suggesting that filamin-A modulates the intra-cellular 
drug kinetics of Topo II poisons to facilitate the generation of DSB after Topo II poison 
exposure. These data suggest a novel function of filamin-A in regulating the pharmacokinetics 
of Topo II poisons, and that the status of filamin-A may be used as a prognostic marker for 
Topo II poisons based cancer treatments. 
Key words: Filamin-A, ABP-280, topoisomerase II poisons, chemotherapy, sensitization. 
Introduction 
Human topoisomerase II (Topo II or Top2) has 
been used as a therapeutic target for the development 
of anticancer drugs [1, 2]. Two classes of Topo II poi-
sons,  anthracyclines  and  epipodophyllotoxins,  have 
been extensively studied [3, 4]. Among them, doxo-
rubicin and etoposide are commonly used in clinical 
practice. These drugs trap Topo II on cleaved DNA to 
form stable cleavage complex, which results in irre-
versible  double-strand  breaks  (DSB),  leading  to  cell 
death [5-8]. Thus the efficacy of Topo II poisons can be 
modulated by both the ability of cells to repair DNA 
damage and the drug transport and/or metabolism. 
Identification of biomarkers that modulate these pro-
cesses  will  greatly  facilitate  individually  tailored 
cancer treatment using Topo II poisons.  
Filamin-A  (FLNa)  is  also  called  Actin  Binding 
Protein-280  (ABP-280)  [9-11].  It  carries  out  versatile 
biological functions in the cell, including organizing 
cortical actin filament networks and acting as a scaf-
fold for signal transduction [9, 12, 13]. Filamin-A in-
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teracts with caveolin-1 to promote caveolae-mediated 
vesicle  internalization,  clustering,  and  trafficking 
[14-16]. It has also been shown that filamin-A regu-
lates  intracellular  sorting  and  redistribution  of  pro-
teins  including  epidermal  growth  factor  receptors 
(EGFR)  and  furin  [17,  18].  We  and  others  have  re-
ported that filamin-A plays a role in the regulation of 
homologous  recombination  (HR)  and 
non-homologous  end  joining  (NHEJ)  through  inter-
actions with BRCA1 and BRCA2 [19, 20]. In this con-
text, filamin-A is required for efficient repair of a va-
riety of DNA damages, including single strand breaks 
(SSBs), double strand breaks (DSBs) and inter-strand 
cross links (ICLs) [19, 20]. In this study, we tested the 
role  of  filamin-A  in  the  modulation  of  the  cellular 
sensitivity to Topo II poisons. Interestingly, we found 
that loss of filamin-A expression did not sensitize cells 
to etoposide and doxorubicin treatments, rather, fil-
amin-A deficient cells are more resistant to these Topo 
II poisons than filamin-A proficient cells. We further 
discovered that filamin-A plays a role in regulating 
the  influx  and  efflux  of  Topo  II  poisons.  Filamin-A 
proficient  cells  incurs  more  Topo  II  poison-induced 
DNA damages compared to filamin-A deficient cells, 
due  to  elevated  intracellular  drug  level.  This  result 
suggests that filamin-A can be used as a prognostic 
marker for Topo II poisons based cancer treatments. 
Materials and Methods 
Cell lines, cell cultures, and cellular sensitivity 
to Topo II poisons 
The three pairs of isogenic filamin-A proficient 
and deficient cell lines have been described in previ-
ous  publications  [19,  21].  These  cells  are:  M2  (fila-
min-A  deficient)  and  A7  (filamin-A  proficient), 
C8161-KD  (filamin-A  knockdown)  and  C8161-Con 
(filamin-A  proficient),  and  MB231-KD  (filamin-A 
knockdown)  and  MB231-Con  (filamin-A  proficient). 
The characterization and culture condition for these 
cells have been described in previous reports [19, 21]. 
Log-phase cells were treated with etoposide or dox-
orubicin, the cellular sensitivity was measured with 
colony formation assay and growth inhibition assay 
as described in a previous report [21]. 
Immunofluorescent detection of γH2AX nu-
clear foci 
Cells (5 × 104) were plated and grown on glass 
coverslips for 16 h, then treated with 10 μM of etopo-
side or 0.25 μg/ml of doxorubicin for 2 hours. Upon 
the completion of 2 hours drug exposure, cells were 
washed with PBS and fed with fresh media to allow 
recovering. At various time points to be specified in 
the  figures,  the  cells  were  fixed  and  stained  for 
γH2AX  nuclear  foci,  using  the  procedures  as  de-
scribed previously [19, 21]. 
Drug influx measured by flow cytometry 
Cells  (5  ×  105)  were  treated  with  5  μg/ml  of 
doxorubicin at 37°C. The cells were collected by cen-
trifugation  at  4°C,  after  continuous  exposure  to  the 
drug  for  0,  10  and  30  min.  After  two  washes  with 
ice-cold PBS, the cells were re-suspended in 0.5 ml of 
ice-cold PBS and kept on ice for flow cytometry anal-
ysis  immediately  to  determine  the  relative  level  of 
intracellular doxorubicin based on the strength of its 
auto-fluorescence.  The  cells  were  analyzed  using  a 
FACS  Calibur  benchtop  flow  cytometer  (BD  Biosci-
ences, San Jose, CA) with excitation at 488 nm, with 
emission integrated above 530 nm. For each sample, 
20,000 cells were analyzed, and experiment was re-
peated twice. 
The efflux of doxorubicin as assessed with flu-
orescent microscopy 
To measure the efflux of doxorubicin, the cells 
were  treated  with  1.0  μg/ml  of  doxorubicin  for  10 
min, and then fixed with cold 4% paraformaldehyde 
at 0, 15 and 30 min after incubation  with drug-free 
medium. Fixed cells were stained with DAPI. Images 
containing  red  and  blue  channels  were  taken  with 
fluorescent  microscope.  The  signal  intensities  from 
red  channel  (doxorubicin)  and  blue  channel  (DNA, 
internal control) were measured with Image J as de-
scribed  before  [22]  and  the  ratio  of  red  signal  over 
blue represents the relative intracellular concentration 
of doxorubicin.  
The efflux of etoposide measured with HPLC 
Because the excitation and emission wavelengths 
of  etoposide  are  out  of  range  of  conventional  flow 
cytometry  and  fluorescent  microscope,  high  perfor-
mance liquid chromatography (HPLC) approach was 
used to measure the efflux of etoposide as described 
before with modification [23]. The HPLC (AKTA Pu-
rifier, GE Healthcare Biosciences, Pittsburgh, PA) is 
equipped  with  UV  detector  and  autosampler.  To 
separate  etoposide,  the  C18  reverse  phase  column 
(ZorBax  SB-C18,  250mm×4.5mm,  Agilent  Technolo-
gies, Santa Clara, CA) was used, and the separation 
was obtained with 50% methanol in H2O as mobile 
phase. To detect etoposide, 220nm of UV wavelength 
was  used.  The  cells  were  treated  with  50  μM  of 
etoposide  for  2  hours,  and  then  harvested  immedi-
ately or after 15 or 30 min of incubation with drug-free 
medium.  Etoposide  within  the  cells  was  extracted 
with diethyl ether and dissolved with mobile phase 
for HPLC analysis. The absorbance of etoposide at 220 Int. J. Biol. Sci. 2012, 8 
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nm of UV was converted into drug concentration us-
ing  premeasured  standard  curve.  Phenacitin  was 
added into cell pellet before diethyl ether extraction 
and used as internal tracer control. 
Tumor growth inhibition with a xenograft 
model 
Among the cell lines used in this study, mela-
noma C8161 forms tumors when subcutaneously in-
oculated, thus was used for the nude mouse xenograft 
experiments. Human melanoma xenogafts were gen-
erated  with  C8161-Con  (filamin-A  wild  type)  and 
C8161-KD (filamin-A knockdown) cells and the tumor 
growth was monitored as described previously [21]. 
When  the  tumor  volume  reached  100-300mm3  after 
5-7  days  of  subcutaneous  injection,  the  xenografts 
were  randomly  divided  into  control  and  treatment 
groups, 5 mice per group. Drug treatment group was 
administrated  with  etoposide  at  the  dosage  of  5 
mg/Kg, with 3 days interval and 7 administrations 
total. Control group was injected with same volume of 
saline. 
Results 
Filamin-A expression sensitizes cells to Topo II 
poisons 
We have shown in previous reports that loss of 
filamin-A sensitizes cells to multiple DNA damaging 
agents,  including  ionizing  radiation,  bleomycin  and 
cisplatin [19, 21]. These studies are in agreement with 
a model that filamin-A is required for efficient DNA 
repair through HR and NHEJ [19-21]. Since Topo II 
poisons  mainly  generate  DSBs  [6,  8],  which  can  be 
repaired  by  HR  and  NHEJ  [24],  we  speculate  that 
filamin-A deficient cells might also be more sensitive 
to Topo II poisons than filamin-A proficient cells. To 
verify this, we treated the same three pairs of isogenic 
filamin-A proficient or deficient cells with etoposide 
and doxorubicin, and measured the cell survival by 
colony formation. To our great surprise, we observed 
an elevated survival among filamin-A deficient cells 
after 2 hours of Topo II poison treatments (Figs. 1A 
and 1B).  
 
Fig. 1. Filamin-A expression sensitizes cells to Topo II poisons. The following three pairs of isogenetic filamin-A proficient and 
deficient cell lines were used (see Materials and Methods for details): M2 (FLNa−) and A7 (FLNa+); C8161-Con (filamin-A control) and 
C8161-KD (filamin-A knockdown); MB231-Con and MB231-KD. Panels A and B are the survival curves assessed by colony formation 
assays. Panel C shows the relative IC50 values of the filamin-A deficient cells normalized to that of the isogenic filamin-A proficient cells (* 
p<0.05, ** p<0.01). The IC50 values were determined by growth inhibition assays (Materials and Methods). Error bars represent the 
standard deviation of at least three independent experiments.  Int. J. Biol. Sci. 2012, 8 
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To confirm this result, we employed growth in-
hibitory assay to measure the IC50s of each cell after 
continuous treatment of cells with etoposide or dox-
orubicin (see Materials and Methods for details). As 
shown in Table 1, filamin-A proficient cells have sig-
nificantly lower IC50 values to etoposide and doxoru-
bicin  than  the  filamin-A  deficient  counterparts 
(p<0.05 or p<0.01). After normalizing the IC50 value to 
that of the paired filamin-A proficient cells, filamin-A 
deficient cells showed 2-3 fold increase in IC50 values 
(Fig. 1C). These data strongly suggest that filamin-A 
deficient cells are less sensitive to etoposide and dox-
orubicin than the filamin-A proficient cells, which is 
in sharp contrast to the sensitivity to ionizing radia-
tion, bleomycin, and cisplatin as reported previously 
[21]. 
 
Table 1. IC50 for human melanoma cell and breast cancer 
cells. 
Cell line  Drug Treatment 
Etoposide (μM)  Doxorubicin (μg/mL) 
A7-FLNa+  0.35±0.12*  0.015±0.003* 
M2-FLNa-  3.38±0.84  0.14±0.02 
C8161-Con  0.87±0.02**  0.045±0.01** 
C8161-KD  4.37±0.15  0.11±0.03 
MB231-Con  0.12±0.06*  0.06±0.01* 
MB231-KD  0.27±0.07  0.13±0.03 
* p<0.05; ** p<0.001. 
 
Induction and repair of DSBs 
DNA Topo II poisons induce DSB and filamin-A 
is required for efficient DSB repair through regulating 
HR  and  NHEJ.  Thus,  it  was  puzzling  to  us  at  the 
moment that filamin-A deficient cells have lesser cel-
lular  sensitivity  to  Topo  II  poisons  than  filamin-A 
proficient cells. To investigate the mechanism of this 
apparently conflicting phenomenon, we assessed the 
initial levels of DNA damage and the repair kinetics. 
Again, we used M2 cells that have spontaneously lost 
filamin-A expression and the A7 cells that have rein-
stated filamin-A by stably expressing filamin-A in the 
M2 cells. After 2 hr exposure to 10 μM of etoposide or 
0.25μg/ml of doxorubicin, the drug was washed out. 
At  various  time  points  as  shown  in  Figure  2A,  the 
numbers of DSB in these paired cells were assessed by 
measuring the number of γH2AX nuclear foci. Signif-
icantly more γH2AX nuclear foci were induced in A7 
cells than in M2 cells after 2 hours of etoposide incu-
bation  (50.7  and  33.3 foci/cell  respectively,  p<0.01), 
indicating that there is more initial DNA damage in 
the filamin-A proficient A7 cells than the deficient M2 
cells (Fig.2A). Similarly, higher peak value of H2AX 
foci was observed in A7 than M2 after doxorubicin 
treatment (Fig. 2B). It is notable that the highest level 
of DSBs induced in doxorubicin treated cells occurs at 
6 hours after the drug was removed, instead of right 
after 2 hour of drug incubation with etoposide (Figs. 
2A and B). This observation is in agreement with pre-
vious study that the generation of cleaved DNA takes 
longer  for  doxorubicin  than  etoposide  [25].  Never-
theless, these data suggest that there was significantly 
less initial amount of DSB generated in M2 than A7 
cells.  
To compare the capability of DSB repair in A7 
and M2 cells, the time-points (Figs. 2A and 2B) after 
the DSB reached the highest level (0 hr for etoposide 
and 6 hr for doxorubicin) were used for exponential 
regression analysis. As shown in Figure 2C and 2D, 
there  are  strong  correlations  between  the  DSB  and 
repair time (R2>0.95) for both drugs. For both etopo-
side and doxorubicin, the A7 cells have deeper slops 
than the M2 cells, indicating more efficient repair of 
DSBs in A7 cells, which is consistent with previous 
report [19-21]. At 22 hours after drug treatment, the 
number of γH2AX foci in both cells decreased dra-
matically, while there was significantly higher num-
ber of residual γH2AX foci in A7 cells than in M2 cells 
(Fig.2A and B).  
Collectively, Figure 2 suggests that A7 cells incur 
more initial DNA damage after Topo II poison treat-
ments. Despite of a faster removal of the DSB, there 
remains more DSBs in A7 cells than M2 cells due to 
the excessive level of initial DSB. The net outcome is 
that  A7  cells  consistently  bear  more  DNA  damage 
during the first 22 hours after 2 hours of treatment, 
which likely contributes to the increased cellular sen-
sitivity to Topo II poison.  
Filamin-A expression increases drug influx and 
decreases drug efflux 
Filamin-A proficient cells showed higher cellular 
sensitivity to Topo II poisons (Fig. 1), and more initial 
DSBs induced in filamin-A expressing A7 cells than 
filamin-A  deficient  M2  cells  (Fig.  2).  The  extent  of 
cleaved DNA generated in cells is thought to be cor-
related with intracellular drug concentration. There-
fore, we tested drug influx of Topo II poisons in A7 
and M2 cells. Since doxorubicin is a natural fluores-
cent compound, we measured the intracellular con-
centration of doxorubicin by measuring the fluores-
cent  intensity  using  flow  cytometry.  The  cells  were 
incubated with 5μg/ml doxorubicin for 0, 15 and 30 
min. As shown in Figure 3A, the fluorescent intensity 
increased  with  the  treatment  time.  Stronger  signals Int. J. Biol. Sci. 2012, 8 
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were detected in A7 cells than M2 cells at 15 and 30 
min after drug treatment, indicating higher intracel-
lular drug concentration in A7 cells after drug expo-
sure. Figure 3B shows the representative histographs 
of flow cytometry and about one fold of signal inten-
sity increases was observed in A7 cells compared with 
M2  cells  at  15  and  30  min  time  points.  This  result 
suggests  the  elevated  drug  intake  in  filamin-A  ex-
pressing cells. 
 
Fig. 2. Induction and repair of DSBs after 2 hours of etoposide and doxorubicin treatment. The A7 (FLNa+) and M2 (FLNa−) 
cells were treated with 10 μM etoposide or 0.25 μg/ml doxorubicin for 2 h, and then the drug was removed and the cells were kept in 
drug-free medium. The cells were fixed at various time points for γH2AX immunostaining. The numbers of γH2AX nuclear foci were 
counted from 100–150 cells in each slide, and the experiment was repeated twice. Panels A and B show the average numbers of γH2AX 
nuclear foci after etoposide (Panel A) or doxorubicin (Panel B) treatment (* p<0.05, ** p<0.01). Error bars are standard deviations. Panel 
C and D show the exponential regression analysis. After DNA damage reached highest level (0 hour for etoposide and 6 hour for 
doxorubicin), the numbers of γH2AX against the repair time were shown in X-Y scattered plot (Diamond and Square). Solid lines are the 
exponential regression fitting. The exponential regression equations along with the coefficient of determination, R-squared (R2), are 
shown in the figure. 
 
Fig. 3. Drug influx of doxorubicin in melanoma A7 and M2 cells. The A7 (FLNa+) and M2 (FLNa−) cells were treated with 5μg/ml 
doxorubicin for 0, 10min and 30min, the intracellular concentration of doxorubicin was assessed by measuring red fluorescent signal using 
flow cytometry. Panel A shows the fluorescent intensity of doxorubicin measured in A7 and M2 cells. Shown is the average of three 
independent experiments, and error bars are standard deviations. Panel B shows the representative histograph of flow cytometry. Int. J. Biol. Sci. 2012, 8 
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Higher intracellular drug concentration may not 
only reflect increased drug influx, but also decreased 
drug  efflux.  To  test  whether  filamin-A  affects  dug 
excretion, we measured the efflux of doxorubicin in 
the paired filamin-A proficient and deficient cells. The 
cells were treated with 1.0 μg/ml of doxorubicin for 
10 min, then were fixed with cold 4% paraformalde-
hyde immediately or after 15 or 30 min incubation in 
drug-free  medium  at  37°C.  After  staining  the  cells 
with DAPI, images containing red and blue channels 
were  taken  with  fluorescent  microscope.  Figure  4A 
shows the representative images of the cells incubated 
in drug-free medium for 15 min.  
 
Fig. 4. Drug efflux in filamin-A proficient and deficient cells. The cells were treated with 1.0 μg/ml of doxorubicin for 10 min, then 
were fixed with cold 4% paraformaldehyde immediately or after 15 or 30 min incubation in drug-free medium. Fixed cells were stained 
with DAPI. Images containing red and blue channels were taken with fluorescent microscope. The signal intensities from red channel 
(doxorubicin) and blue channel (DNA, internal control) were measured with Image J as described before[22]. The ratio of red signal over 
blue reflects the intracellular concentration of doxorubicin. Panel A shows the representative images taken after 15 min drug efflux. Panel 
B shows quantitative data of intracellular concentration of doxorubicin with various time drug excretions (* p<0.05, ** p<0.01). 40 cells 
were analyzed from each slide and shown are the averages from three independent experiments. Error bars are standard errors. To assess 
the efflux of etoposide, A7 and M2 cells were treated with 50 μM etoposide for 2 hours, and then the cells were harvested immediately 
or after 15 or 30 min incubation in drug-free medium. The amount of etoposide in the cells was determined with HPLC (Materials and 
Methods). Panel C shows the intracellular concentration of etoposide of A7 and M2 cells. Shown are the averages from three independent 
experiments. Error bars are standard errors. Int. J. Biol. Sci. 2012, 8 
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We  analyzed  signal  intensity  using  Image  J 
software as described before[22]. Stronger red signals 
(doxorubicin) were observed in filamin-A proficient 
cells  (A7-FLNa+,  C8161-Con  and  MB231-Con)  than 
filamin-A  deficient  cells  (M2,  C8161-KD  and 
MB231-KD). After taking the ratio of red signal over 
blue signal which reflects the intracellular concentra-
tion of doxorubicin, significant slow drug efflux was 
observed in filamin-A expressing cells than filamin-A 
deficient cells (Fig. 4B). 
To assess the efflux of etoposide, we employed 
HPLC  equipped  with  UV  detector  to  measure  in-
tra-cellular  levels  of  etoposide.  As  shown  in  Figure 
4C,  significantly  faster  etoposide  excretion  was  de-
tected in filamin-A deficient cells (M2 and MB231-KD) 
than filamin-A proficient cells (A7 and MB231-Con). 
These data suggest that filamin-A expression affects 
the cellular drug kinetics of Topo II poisons including 
etoposide and doxorubicin, by increasing drug influx 
and decreasing drug efflux (Figs. 3 and 4), which may 
contribute to the increased toxicity to filamin-A pro-
ficient cells.  
Filamin-A expression sensitizes the tumor 
xenografts to Topo II poisons 
We  have  shown  that  filamin-A  expression  in-
creases the cellular sensitivity to Topo II poisons (Figs. 
1  and  2),  and  this  sensitization  effect  is  the  conse-
quence of increased drug influx and decreased drug 
efflux  in  filamin-A  proficient  cells  (Figs.  3  and  4). 
These data raise a possibility that filamin-A may be 
used as a prognostic marker for cancer treatment with 
Topo II poisons. To verify this, we generated human 
melanoma tumor xenografts with paired C8161 cell 
lines (C8161-Con and C8161-KD). The tumor growth 
was monitored during control (saline) and etoposide 
treatments. Both control (C8161-Con) and filamin-A 
knockdown  (C8161-KD)  cells  formed  xenograft  tu-
mors in nude mice with similar growth rates (Fig. 5). 
As expected, xenograft tumors treated with etoposide 
(5  mg/kg)  displayed  growth  delay  compared  with 
those  treated  with  saline  alone.  Furthermore,  fila-
min-A  proficient  tumors  grew  significantly  slower 
than the filamin-A deficient tumors (p < 0.05) at 24 
days with etoposide treatments, suggesting that fila-
min-A  expression  significantly  sensitizes  melanoma 
cells to etoposide (Fig. 5). These data indicate that lack 
of filamin-A expression impairs the efficacy of Topo II 
poisons in cancer treatment. 
 
 
 
Fig. 5. Filamin-A expression sensitizes C8161 melanoma cells to etoposide treatment in xenograft mouse model. Hu-
man melanoma tumor xenografts were generated as described previously. Shown is the tumor growth in response to control (saline) and 
etoposide treatment. Treatment group was administrated with etoposide at the dosage of 5 mg/Kg, with 3 days interval and 7 admin-
istrations total. Control group was injected with same volume of saline. Error bars represent the standard errors from 5 mice. Red arrow 
shown in figure indicates the significant growth delay was observed in filamin-A proficient tumors compared with filamin-A deficient 
tumors (p < 0.05) at 24 days and thereafter with etoposide treatments. 
 Int. J. Biol. Sci. 2012, 8 
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Discussion 
Etoposide and doxorubicin are among the most 
commonly  used  agents  in  clinical  cancer  treatment. 
They interfere with the rejoining reaction of cleaved 
DNA by stabilizing the covalent Topo II-DNA com-
plex, which in turn generates DSBs that can be visu-
alized as γH2AX nuclear foci. In this report, we illus-
trate a novel function of filamin-A in regulating Topo 
II poison intracellular pharmacokinetics. Lack of fil-
amin-A  expression  decreases  the  intracellular  drug 
levels, reduces the amount of DNA damage caused by 
etoposide  and  doxorubicin,  and  subsequently  abro-
gates cell sensitivity to these Topo II poisons.  
Filamin-A is depicted as multifunctional protein 
with variety of interacting partners. It  is not only an 
essential component of the cytoskeleton networks, but also 
serves as the scaffold in various signaling networks (see 
reviews [13, 26, 27]). Recently, it has been shown that 
filamin-A  regulates  HR  and  NHEJ  and  thus  modu-
lates  DNA  damage  repair  [19,  20].  Consistent  with 
these  reports,  we  observed  a  faster  removal  of 
drug-induced DSBs in filamin-A proficient cells than 
deficient cells during the period of DSB repair (Fig. 2C 
and D), confirming the role of filamin-A in DNA re-
pair.  However,  filamin-A  proficient  cells  also  have 
higher levels of  initial amount of  DNA damage in-
duced  by  both  etoposide  and  doxorubicin  (Fig.  2A 
and B). The net outcome of these two opposing effects 
is the constantly higher levels of DNA damage in the 
filamin-A  proficient  cells  than  the  deficient  cells,  at 
least within the first 22 hours after the removal of the 
drugs  (Figure  2).  We  believe  that  this  is  likely  the 
main  determinant  in  the  increased  sensitivity  to 
etoposide  and  doxorubicin  among  filamin-A  profi-
cient cells.  
We further demonstrated that the elevated level 
of initial DNA damage in filamin-A proficient cells is 
strongly supported by the increased intracellular drug 
concentration  in  these  cells.  As  shown  in  Figure  3, 
filamin-A proficient cells  have an elevated drug in-
take  compared  to  deficient  cells  as  soon  as  15  min 
after  doxorubicin  was  added  into  the  medium.  At 
30min  after  continuously  exposure,  A7  cells  have 
about one fold increase of intracellular doxorubicin. 
At the same time, after the drugs are removed, the 
filamin-A proficient cells also have slower clearance 
of  intracellular  doxorubicin  and  etoposide  (Fig.  4), 
suggesting that the expression of filamin-A decreases 
the efflux of Topo II poisons.  
The  mechanisms  of  how  filamin-A  affects  the 
drug influx and efflux remain elusive. It is known that 
influx of drug into the cells may take place by simple 
diffusion.  In  multidrug  resistant  cells  (with 
P-glycoprotein  expression),  increased  efflux  can  be 
accompanied by a decrease in influx [28, 29], which is 
similar to what we have found in filamin-A deficient 
cells.  However,  the  expression  of  P-glycoprotein 
(MDR-1), the main drug transporter [30], was below 
the detectable level in the cell lines used in this study, 
as shown in our previous report[21]. Thus, alternative 
mechanisms  remain  to  be  investigated.  It  is  known 
that other membrane proteins in addition to MDR-1, 
such as ATP-binding cassette (ABC) transporters and 
multidrug  resistance-associated  protein  (MRP),  may 
promote  the  efflux  of  etoposide  and  doxorubicin 
[31-33]. Filamin-A has been reported to play a role in 
intracellular  trafficking  and  redistribution  of  some 
proteins, such as epidermal growth factor receptors 
(EGFR)  and  furin  [17,  18].  Thus,  it  is  possible  that 
filamin-A may regulate drug efflux by affecting the 
cellular trafficking or membrane distribution of these 
proteins  which  are  responsible  for  the  drug  trans-
porting.  In  addition,  filamin-A  has  been  shown  to 
interact  with  caveolin-1  and  promote  caveo-
lae-mediated  vesicle  internalization,  clustering,  and 
trafficking [14-16]. Both endocytosis and intracellular 
vesicle trafficking have been shown to affect the in-
take of hormone, protein, and lipids. It remains to be 
determined whether this activity also contributes to 
the intake of Topo II poisons.  
Although  the  mechanism  by  which  filamin-A 
regulates the intake and efflux of Topo II poisons re-
quires further investigation, our study raises a possi-
bility that filamin-A can be used as a biomarker for 
cancer  treatment  by  Topo  II  poisons.  As  shown  in 
previous study, about 40-50% of melanoma and breast 
tumors are filamin-A positive [19, 21]. It is likely that 
these patients will have better prognosis in terms of 
response to Topo II poisons based chemotherapy due 
to  higher  intracellular  drug  concentration  than  fila-
min-A  deficient  cancers.  However,  they  will  have 
poorer prognosis to radiation, bleomycin, and cispla-
tin  treatments,  due  to  enhanced  ability  to  repair 
damaged DNA. Therefore, the status of filamin-A can 
be used to differentiate the selection of different types 
of DNA damage based treatments, serving as an im-
portant biomarker for individualized treatment.  
In summary, our current study greatly expands 
the spectrum of filamin-A’s function, regulating the 
pharmacokinetics of Topo II poisons. Combining with 
previous  studies,  filamin-A  can  be  used  as  a  bi-
omarker for individually tailored therapeutic regimes 
establishment. The previous reports [19, 21] and this 
study suggest that, for cancers expressing filamin-A, 
Topo II poisons based therapy is a better choice than 
radiation,  bleomycin,  and  cisplatin.  For  filamin-A Int. J. Biol. Sci. 2012, 8 
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deficient cancers, radiation, bleomycin and cisplatin 
would be a better choice than Topo II poisons.  
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